This result suggests that long-term management of blood lipid profiles is necessary for BC patients who have received NAC, especially in patients who also require endocrine therapy, such as tamoxifen and aromatase inhibitors, which could alter lipid profiles in different ways (36, 37). The gene discussed is CYP19A1; the disease is breast cancer.